Story highlights FDA finds "no significant impact" of genetically modified mosquito on health or environment

A field trial could follow the results of a local referendum in November

(CNN) It's another win for the GMO mosquito.

After months of reviewing public comments to its draft environmental impact study, the Food and Drug Administration announced today that it is officially giving OX513A , a genetically modified male mosquito developed by British company, Oxitec, a clean bill of health. The decision gives the federal green light for the use of the mosquito in a field trial this fall in a small Florida neighborhood.

"We're really pleased to announce the FDA finished their review and has found no significant impact of the release of our mosquito on human health or the environment," Oxitec CEO Hadyn Parry said. "This is especially timely, given the recent finding of Zika transmission by local mosquitoes in a Miami neighborhood."

OX513A is a male Aedes aegypti mosquito, the primary species that carries the Zika virus. He is genetically engineered to pass along a lethal gene to wild females that makes the females' offspring die. The gene creates a protein that interferes with cell activity, killing the mosquito before it can reach adulthood.

The field trial in Key Haven, Florida, is designed to test how well OX513A controls the local population of Aedes aegypti. Key Haven is a small community of about 475 homes on Raccoon Key, about a mile east of the island of Key West.

Read More